RNA News and Press, Avidity Biosciences Inc. From 11/01/25

2025-11-01 15:15:34 ET More on M&A tickers, etc. DocGo: Revenue Collapse Overshadows Acquisition, Is Cheap But Still A Hold Blackstone Q3: Distributable Earnings Up +48% (Rating Upgrade) Old Republic International Corporation (ORI) Q3 2025 Earnings Call Transcrip...

2025-10-31 09:44:45 ET Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per share. The deal values Avidity at $12 billion. However...

Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights PR Newswire Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Oct. 30, 2025 /PRNewswire/ -- Halper Sadeh LL...

2025-10-29 17:50:28 ET The last time I wrote about PepGen ( PEPG ) it was with respect to a Seeking Alpha article entitled " PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope of Current Treatments ". With respect to this article, I spoke about the potential i...

2025-10-28 17:13:38 ET The markets continued to grind up despite myriad concerns, including a government shutdown that soon will enter its fifth week with no resolution in sight. There does seem to be some recent progress around some sort of trade deal or at least some potential detente...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidi...

2025-10-28 05:37:41 ET Keay Nakae from Chardan Capital issued a price target of $72.00 for RNA on 2025-10-28 08:21:46. The adjusted price target was set to $72.00. At the time of the announcement, RNA was trading at $70. The overall price target consensus is at $75.67 wi...

2025-10-28 04:13:20 ET More on Novartis Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats Novartis AG (NVS) M&A Call Transcript Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution Novartis reports mixed Q3 r...

2025-10-27 17:08:35 ET Investment Overview: Novartis Set To Acquire Avidity - Rationale & Commentary Yesterday, the Swiss Pharma giant Novartis AG ( NVS ) - the world's fourth most valuable Pharma by market cap, currently ~$249bn - announced that it would acquire the...

A look at the top 10 most actives in the United States Co-Diagnostics Inc. (CODX) rose 259.3% to $1.26 on volume of 1,091,982,272 shares Strive Inc. (ASST) rose 49.1% to $1.64 on volume of 1,039,234,617 shares BigBear.ai Inc. (BBAI) rose 0.7% to $7.1 on volume of 351,989,235 shares Beyond...